| 摘要 |
The present invention relates to the adenosine A3 receptor ligands of the general formula (I), within them favourably to the antagonists, to their salts, solvates,-oxides and isomers, to the pharmaceutical compositions containing the compounds of the general formula (I), their salts, solvates,-oxides and isomers, to the use of the compounds of the general formula (I), their salts, solvates,-oxides and isomers, to the preparation of the compounds of the general formula (I), their salts, solvates,-oxides and isomers, as well as to the new intermediates of the general formula (II), (VI), (XI), (XII) and (XV), and to the preparation thereof.
|
